Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
STE - STERIS plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$271.33
DETAILS
HIGH:
$275.00
LOW:
$269.00
MEDIAN:
$270.00
CONSENSUS:
$271.33
UPSIDE:
14.04%
Stock News
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
STERIS Q1 Earnings Call Highlights
STERIS (NYSE: STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from the prior-year quarter, while constant-currency organic revenue rose 6%, driven by volume growth and 190
STERIS Q1 Earnings Call Highlights
STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
STERIS plc (STE) Q1 2027 Earnings Call Transcript
STERIS plc (STE) Q1 2027 Earnings Call Transcript
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
5 Quality Stocks Set to Reward Investors With Dividend Hikes
Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.
Here's What Key Metrics Tell Us About Steris (STE) Q1 Earnings
While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Steris (STE) Q1 Earnings Surpass Estimates
Steris (STE) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.34 per share a year ago.
STERIS Announces Financial Results for Fiscal 2027 First Quarter
DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.
Steris to invest $600 million in new North Carolina chemicals manufacturing hub
Medical equipment maker Steris said on Wednesday it will invest $600 million to build a manufacturing and distribution hub in North Carolina for chemicals used by healthcare and pharmaceutical customers.
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries
STERIS Raises Dividend to $0.69 per share
DUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. This represents a $0.06 increase in the dividend and the Company's 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 4, 2026.
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?
STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18.
Entropy Technologies LP Has $2.19 Million Holdings in STERIS plc $STE
Entropy Technologies LP lessened its position in shares of STERIS plc (NYSE: STE) by 25.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,899 shares of the medical equipment provider's stock after selling 3,398 shares during the period. Entropy Technologies LP's holdings
STERIS plc $STE Shares Acquired by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership boosted its stake in shares of STERIS plc (NYSE: STE) by 20.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 519,511 shares of the medical equipment provider's stock after purchasing an additional 88,872 shares during
Why Steris (STE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Steris (STE) Up 1% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Price Targets
Steris initiated with a Buy at UBS
$275.00
(was $218.40)
Patrick Wood
·
UBS
Piper Sandler: 'Is now the time to buy STERIS (STE)?'
$270.00
(was $216.18)
Jason Bednar
·
Piper Sandler
Steris price target lowered to $269 from $291 at KeyBanc
$269.00
(was $210.85)
Brett Fishbin
·
KeyBanc
Piper Sandler Upgrades STERIS (STE) to Overweight
$260.00
(was $221.15)
Jason Bednar
·
Piper Sandler
Steris price target raised to $265 from $255 at KeyBanc
$265.00
(was $241.10)
Brett Fishbin
·
KeyBanc
STERIS (STE) PT Raised to $225 at Piper Sandler
$225.00
(was $225.94)
Jason Bednar
·
Piper Sandler
STERIS (STE) PT Raised to $245 at Wolfe Research
$245.00
(was $216.65)
Mike Polark
·
Wolfe Research